
    
      An open label prospective study is performed to investigate the effectiveness and safety of
      ustekinumab in hidradenitis suppurativa. Twenty patients will be included. They will receive
      ustekinumab 45 or 90 mg on weeks 0-4-16-28. Patients will be followed up untill week 40.
    
  